AR121600A1 - Compuestos de oxoisoindolina sustituidos - Google Patents
Compuestos de oxoisoindolina sustituidosInfo
- Publication number
- AR121600A1 AR121600A1 ARP210100671A ARP210100671A AR121600A1 AR 121600 A1 AR121600 A1 AR 121600A1 AR P210100671 A ARP210100671 A AR P210100671A AR P210100671 A ARP210100671 A AR P210100671A AR 121600 A1 AR121600 A1 AR 121600A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- independently
- phenyl
- zero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una sal del mismo, en donde: El anillo A es: un compuesto seleccionado del grupo de fórmulas (2); cada R¹ es independientemente F, Cl, Br, -CN, -OH, -NO₂, alquilo C₁₋₆ sustituido por cero a 6 R¹ᵃ, alcoxi C₁₋₃ sustituido por cero a 6 R¹ᵃ, -CRˣRˣOCRˣRˣ(fenilo), -NRʸRʸ, -NRˣC(O)H, -NRˣC(O)(alquilo C₁₋₂), -NRˣC(O)NRˣRˣ, -C(O)H, -C(O)OH, -C(O)O(alquilo C₁₋₃), -C(O)NRˣRˣ, -C(O)NRˣ(cicloalquilo C₃₋₆), -OC(O)(alquilo C₁₋₃), -SO₂(alquilo C₁₋₃), -NHN(alquilo C₁₋₂)₂, -CH₂CH₂Si(CH₃)₃ o un grupo cíclico seleccionado de cicloalquilo C₃₋₆, fenilo, piridinilo, piperidinilo, piperazinilo, pirrolidinilo, morfolinilo, y dioxidotiomorfolinilo, en donde dicho grupo cíclico se sustituye por cero a 4 R¹ᵇ; cada R¹ᵃ es independientemente F, Cl, -CN, -OH, alcoxi C₁₋₂, fluoroalcoxi C₁₋₂, -SO₂(alquilo C₁₋₃), o fenilo; cada R¹ᵇ es independientemente F, Cl, alquilo C₁₋₂, fluoroalquilo C₁₋₂, alcoxi C₁₋₂, fluoroalcoxi C₁₋₂, -C(O)(alquilo C₁₋₃), -SO₂(alquilo C₁₋₃), o -CH₂(fenilo); cada Rˣ es independientemente H o -CH₃; cada Rʸ es independientemente H o alquilo C₁₋₆; y n es cero, 1, 2, 3, ó 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062993144P | 2020-03-23 | 2020-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121600A1 true AR121600A1 (es) | 2022-06-22 |
Family
ID=75478287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100671A AR121600A1 (es) | 2020-03-23 | 2021-03-18 | Compuestos de oxoisoindolina sustituidos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230322803A1 (es) |
EP (1) | EP4126843A1 (es) |
JP (1) | JP2023520759A (es) |
KR (1) | KR20220158256A (es) |
CN (1) | CN115605466A (es) |
AR (1) | AR121600A1 (es) |
AU (1) | AU2021241458A1 (es) |
BR (1) | BR112022018706A2 (es) |
CA (1) | CA3172626A1 (es) |
IL (1) | IL296676A (es) |
MX (1) | MX2022011601A (es) |
TW (1) | TW202140441A (es) |
WO (1) | WO2021194914A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical preparations that modulate IKZF2 |
US20230242508A1 (en) * | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202345797A (zh) * | 2022-03-25 | 2023-12-01 | 美商昂科皮治療公司亦以普羅提歐凡治療公司名稱營業 | 作為ikzf2降解劑之含雙環雜芳基化合物 |
CN114702440A (zh) * | 2022-04-26 | 2022-07-05 | 永农生物科学有限公司 | 一种氨氯吡啶酸的制备方法及制备的氨氯吡啶酸 |
WO2024096753A1 (en) * | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | ANTI-GITRANT ANTIBODIES |
ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
BR112012013717B1 (pt) | 2009-12-10 | 2020-01-28 | Hoffmann La Roche | anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo |
LT2542256T (lt) | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas |
CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
CN102918060B (zh) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
LT2566517T (lt) | 2010-05-04 | 2019-01-10 | Five Prime Therapeutics, Inc. | Antikūnai, surišantys csf1r |
RU2551963C2 (ru) | 2010-09-09 | 2015-06-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1вв |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
WO2013119716A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
EP2890398A4 (en) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
CN104230787B (zh) * | 2014-08-20 | 2016-08-24 | 华东师范大学 | N-(1,3-二氧代异吲哚啉)芳酰胺类化合物及其制备方法和应用 |
KR102173464B1 (ko) * | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
WO2019079569A1 (en) * | 2017-10-18 | 2019-04-25 | Novartis Ag | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN |
FI3820573T3 (fi) * | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
MX2022005839A (es) * | 2019-11-19 | 2022-06-09 | Bristol Myers Squibb Co | Compuestos utiles como inhibidores de la proteina helios. |
-
2021
- 2021-03-17 TW TW110109618A patent/TW202140441A/zh unknown
- 2021-03-18 AR ARP210100671A patent/AR121600A1/es unknown
- 2021-03-22 US US17/913,206 patent/US20230322803A1/en active Pending
- 2021-03-22 KR KR1020227036360A patent/KR20220158256A/ko unknown
- 2021-03-22 EP EP21718401.9A patent/EP4126843A1/en active Pending
- 2021-03-22 CA CA3172626A patent/CA3172626A1/en active Pending
- 2021-03-22 CN CN202180022533.8A patent/CN115605466A/zh active Pending
- 2021-03-22 JP JP2022557736A patent/JP2023520759A/ja active Pending
- 2021-03-22 MX MX2022011601A patent/MX2022011601A/es unknown
- 2021-03-22 BR BR112022018706A patent/BR112022018706A2/pt unknown
- 2021-03-22 WO PCT/US2021/023382 patent/WO2021194914A1/en unknown
- 2021-03-22 AU AU2021241458A patent/AU2021241458A1/en active Pending
- 2021-03-22 IL IL296676A patent/IL296676A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022018706A2 (pt) | 2022-11-01 |
KR20220158256A (ko) | 2022-11-30 |
EP4126843A1 (en) | 2023-02-08 |
JP2023520759A (ja) | 2023-05-19 |
CA3172626A1 (en) | 2021-09-30 |
AU2021241458A1 (en) | 2022-11-24 |
TW202140441A (zh) | 2021-11-01 |
WO2021194914A1 (en) | 2021-09-30 |
US20230322803A1 (en) | 2023-10-12 |
MX2022011601A (es) | 2022-10-18 |
CN115605466A (zh) | 2023-01-13 |
IL296676A (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121600A1 (es) | Compuestos de oxoisoindolina sustituidos | |
AR093767A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos | |
AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
HRP20231467T1 (hr) | Spojevi | |
RU2017123878A (ru) | Пиколинамидные соединения с фунгицидной активностью | |
AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
AR100712A1 (es) | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t | |
AR109438A1 (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
IN2014KN02940A (es) | ||
AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
EA201690879A1 (ru) | Новое триазолопиридиновое соединение | |
EA201100009A1 (ru) | Соединения 1,2-бензизотиазола, полезные для борьбы с животными-вредителями | |
AR102480A1 (es) | ALCOHOLES TRIFLUOROMETÍLICOS COMO MODULADORES DE RORgt | |
AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
AR101591A1 (es) | Compuestos bicíclicos sustituidos | |
AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos | |
PH12019500589A1 (en) | Novel mesoionic insecticidal compound | |
CL2020002579A1 (es) | Compuesto de fenoxiurea y un agente de control de plagas. | |
AR100767A1 (es) | Agentes moduladores de la atx |